Veru’s (VERU) “Buy” Rating Reaffirmed at HC Wainwright

Veru (NASDAQ:VERU)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $3.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 361.54% from the company’s previous close.

Separately, Oppenheimer reiterated an “outperform” rating and issued a $5.00 price objective on shares of Veru in a report on Tuesday, November 5th.

Veru Stock Up 3.3 %

NASDAQ VERU opened at $0.65 on Friday. The firm has a market cap of $95.15 million, a price-to-earnings ratio of -1.35 and a beta of -0.50. Veru has a 12-month low of $0.36 and a 12-month high of $1.92. The company has a 50-day simple moving average of $0.74 and a two-hundred day simple moving average of $0.81.

Veru (NASDAQ:VERU) last issued its earnings results on Monday, December 16th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. Equities analysts expect that Veru will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Veru

Several institutional investors and hedge funds have recently modified their holdings of VERU. Perceptive Advisors LLC increased its position in shares of Veru by 26.5% during the second quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock valued at $5,942,000 after buying an additional 1,478,578 shares during the period. PVG Asset Management Corp bought a new stake in Veru during the 2nd quarter valued at approximately $474,000. Bank of New York Mellon Corp grew its holdings in shares of Veru by 1,718.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock worth $373,000 after acquiring an additional 419,374 shares during the period. Choreo LLC raised its position in shares of Veru by 261.3% in the 2nd quarter. Choreo LLC now owns 332,050 shares of the company’s stock worth $292,000 after acquiring an additional 240,134 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Veru in the 2nd quarter worth approximately $161,000. 47.16% of the stock is owned by hedge funds and other institutional investors.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.